Javascript must be enabled to continue!
The effect of anti-IL-6 receptor antibody for the treatment of McH-lpr/lpr-RA1 mice that spontaneously developed ankylosing arthritis
View through CrossRef
Abstract[Background]McH-lpr/lpr-RA1 mice are a new strain of mice which spontaneously develop arthritis in the ankle, leading finally to ankylosis. There is no published data that drug treatment has been trialed on these mice.[Objectives]This study examined the effect of the mouse anti-IL-6 receptor antibody, MR16-1, for the treatment of ankylosis in McH-lpr/lpr-RA1 mice.[Methods]Male McH-lpr/lpr-RA1 mice were randomly divided into control and treatment groups. MR16-1 was administered from 10 weeks of age for the treatment group. Saline was applied for the control group. The drug was administered once a week, at an initial dose of 2 mg, then maintained at 0.5 mg once per week thereafter. The effects were evaluated by the histopathological synovitis score, in vivo imaging using indocyanine green liposomes, and analysis of the gene expression of inflammatory cytokines.[Results]Tissue analyses were carried out at 14, 17 and 20 weeks of age. The synovitis scores of treated groups were significantly lower compared with those of the control group at every age. The kappa coefficient was 0.77. However, progression of ankylosis persisted in the MR16-1 treated group. In vivo imaging using indocyanine green liposomes showed significant decreases in signal intensities of treated groups at week 14, but no significant differences were observed at week 18. Blood serum amyloid A levels in treated groups were significantly lower at 17 weeks of age. The gene expression levels of Tnf and Il17 were also significantly lower in MR16-1 treated groups.[Conclusions]Administration of the anti-IL-6 receptor antibody is effective for the treatment of synovitis and bone destruction of McH-lpr/lpr-RA1 mice. McH-lpr/lpr-RA1 mice may be a suitable experimental model for the development of new treatments for spondyloarthritis. IL6 signal blockade could contribute to the treatment of spondyloarthritis, and further studies should be carried out to confirm its potential in the prevention of deformity associated with ankylosis.
Cold Spring Harbor Laboratory
Title: The effect of anti-IL-6 receptor antibody for the treatment of McH-lpr/lpr-RA1 mice that spontaneously developed ankylosing arthritis
Description:
Abstract[Background]McH-lpr/lpr-RA1 mice are a new strain of mice which spontaneously develop arthritis in the ankle, leading finally to ankylosis.
There is no published data that drug treatment has been trialed on these mice.
[Objectives]This study examined the effect of the mouse anti-IL-6 receptor antibody, MR16-1, for the treatment of ankylosis in McH-lpr/lpr-RA1 mice.
[Methods]Male McH-lpr/lpr-RA1 mice were randomly divided into control and treatment groups.
MR16-1 was administered from 10 weeks of age for the treatment group.
Saline was applied for the control group.
The drug was administered once a week, at an initial dose of 2 mg, then maintained at 0.
5 mg once per week thereafter.
The effects were evaluated by the histopathological synovitis score, in vivo imaging using indocyanine green liposomes, and analysis of the gene expression of inflammatory cytokines.
[Results]Tissue analyses were carried out at 14, 17 and 20 weeks of age.
The synovitis scores of treated groups were significantly lower compared with those of the control group at every age.
The kappa coefficient was 0.
77.
However, progression of ankylosis persisted in the MR16-1 treated group.
In vivo imaging using indocyanine green liposomes showed significant decreases in signal intensities of treated groups at week 14, but no significant differences were observed at week 18.
Blood serum amyloid A levels in treated groups were significantly lower at 17 weeks of age.
The gene expression levels of Tnf and Il17 were also significantly lower in MR16-1 treated groups.
[Conclusions]Administration of the anti-IL-6 receptor antibody is effective for the treatment of synovitis and bone destruction of McH-lpr/lpr-RA1 mice.
McH-lpr/lpr-RA1 mice may be a suitable experimental model for the development of new treatments for spondyloarthritis.
IL6 signal blockade could contribute to the treatment of spondyloarthritis, and further studies should be carried out to confirm its potential in the prevention of deformity associated with ankylosis.
Related Results
Lymphadenopathy induced by the cooperation between lprcg and gld genes is of lpr but not of gld phenotype
Lymphadenopathy induced by the cooperation between lprcg and gld genes is of lpr but not of gld phenotype
AbstractMice homozygous for the lpr (lymphoproliferation), lprcg or gld (generalized lymphoproliferative disease) mutation develop strikingly similar lymphadenopathy with expansion...
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
The followina are abstracts of papers presented at the 35th Annual Scientific Meeting of the Australian Rheumatology Association, held in Perth, Western Australia, 1–4 December. 19...
Pengaruh Sosialisasi Buku KIA Terhadap Pengetahuan Ibu Hamil Tentang Buku KIA
Pengaruh Sosialisasi Buku KIA Terhadap Pengetahuan Ibu Hamil Tentang Buku KIA
ABSTRACT The implementation of the MCH Handbook is still not optimal, there are still many mothers, families, health workers, and cadres who have not carried out the things that sh...
Functional distinctions between MRL-lpr and MRL-gld lymphocytes. Normal cells reverse the gld but not lpr immunoregulatory defect.
Functional distinctions between MRL-lpr and MRL-gld lymphocytes. Normal cells reverse the gld but not lpr immunoregulatory defect.
Abstract
Homozygosity for either of the autosomal recessive mutations, lpr or gld, confers an autoimmune syndrome characterized by massive lymphoid hyperplasia and e...
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
CYTOKINES IN SLE: LESSONS FROM EXPERIMENTAL MODELS AND MAN, Michael J Elliott*., Peter Charles, Ravinder N MainiTHE FAS GENE IN HUMAN LUPUS: THE EXPRESSION OF VARIANT TRANSCRIPTS.,...
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
Objectives
Low density lipoprotein receptor defect mice model by transgenetic technology was used to detect atherosclerosis by Ultrasound Biology (UBM). And evalu...
Autoantibody Profile in Systemic Lupus Erythematosus Patients
Autoantibody Profile in Systemic Lupus Erythematosus Patients
AbstractSystemic lupus erythematosus (SLE) is an autoimmune disease, in which the etiology is not well-understood; however, interactions between environmental and genetic factors i...
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract
Introduction: TIGIT and Lag3 are inhibitory receptors expressed on cytotoxic CD8+ T cells and NK cells and directly inhibit the activation and proliferation...

